MARTI TECHNOLOGIES INC (MRT) Fundamental Analysis & Valuation

NYSEARCA:MRT • US5731341039

Current stock price

2 USD
0 (0%)
At close:
2.0027 USD
+0 (+0.13%)
After Hours:

This MRT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MRT Profitability Analysis

1.1 Basic Checks

  • MRT had negative earnings in the past year.
  • In the past year MRT has reported a negative cash flow from operations.
  • MRT had negative earnings in each of the past 5 years.
  • In the past 5 years MRT always reported negative operating cash flow.
MRT Yearly Net Income VS EBIT VS OCF VS FCFMRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -183.73%, MRT is doing worse than 95.24% of the companies in the same industry.
Industry RankSector Rank
ROA -183.73%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRT Yearly ROA, ROE, ROICMRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -0.5 -1 -1.5

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRT Yearly Profit, Operating, Gross MarginsMRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -100 -200 -300

2

2. MRT Health Analysis

2.1 Basic Checks

  • MRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRT Yearly Shares OutstandingMRT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M
MRT Yearly Total Debt VS Total AssetsMRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M

2.2 Solvency

  • MRT has an Altman-Z score of -5.62. This is a bad value and indicates that MRT is not financially healthy and even has some risk of bankruptcy.
  • MRT has a worse Altman-Z score (-5.62) than 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.62
ROIC/WACCN/A
WACC10.69%
MRT Yearly LT Debt VS Equity VS FCFMRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 1.47 indicates that MRT should not have too much problems paying its short term obligations.
  • MRT has a Current ratio of 1.47. This is in the better half of the industry: MRT outperforms 64.29% of its industry peers.
  • MRT has a Quick Ratio of 1.32. This is a normal value and indicates that MRT is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.32, MRT is in the better half of the industry, outperforming 61.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.32
MRT Yearly Current Assets VS Current LiabilitesMRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M 8M 10M

3

3. MRT Growth Analysis

3.1 Past

  • MRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.39%.
  • MRT shows a decrease in Revenue. In the last year, the revenue decreased by -6.84%.
EPS 1Y (TTM)-87.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
Revenue 1Y (TTM)-6.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%70.37%

3.2 Future

  • Based on estimates for the next years, MRT will show a very strong growth in Earnings Per Share. The EPS will grow by 32.77% on average per year.
  • Based on estimates for the next years, MRT will show a very strong growth in Revenue. The Revenue will grow by 68.50% on average per year.
EPS Next Y11.35%
EPS Next 2Y30.19%
EPS Next 3Y32.77%
EPS Next 5YN/A
Revenue Next Year105.31%
Revenue Next 2Y99.81%
Revenue Next 3Y105.8%
Revenue Next 5Y68.5%

3.3 Evolution

MRT Yearly Revenue VS EstimatesMRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRT Yearly EPS VS EstimatesMRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6 -0.8

1

4. MRT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRT Price Earnings VS Forward Price EarningsMRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRT Per share dataMRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • MRT's earnings are expected to grow with 32.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.19%
EPS Next 3Y32.77%

0

5. MRT Dividend Analysis

5.1 Amount

  • MRT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

MRT Fundamentals: All Metrics, Ratios and Statistics

MARTI TECHNOLOGIES INC

NYSEARCA:MRT (3/23/2026, 8:07:42 PM)

After market: 2.0027 +0 (+0.13%)

2

0 (0%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)09-22
Earnings (Next)04-27
Inst Owners13.97%
Inst Owner Change20.87%
Ins Owners35.9%
Ins Owner Change0%
Market Cap157.42M
Revenue(TTM)18.66M
Net Income(TTM)-73.88M
Analysts77.78
Price Target5.1 (155%)
Short Float %0.35%
Short Ratio3.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-3.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.24
BVpS-0.42
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -183.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.62%
Cap/Sales 3.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.32
Altman-Z -5.62
F-Score4
WACC10.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
EPS Next Y11.35%
EPS Next 2Y30.19%
EPS Next 3Y32.77%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%70.37%
Revenue Next Year105.31%
Revenue Next 2Y99.81%
Revenue Next 3Y105.8%
Revenue Next 5Y68.5%
EBIT growth 1Y-118.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.46%
EBIT Next 3Y40.2%
EBIT Next 5Y27.85%
FCF growth 1Y-17.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.23%
OCF growth 3YN/A
OCF growth 5YN/A

MARTI TECHNOLOGIES INC / MRT Fundamental Analysis FAQ

What is the fundamental rating for MRT stock?

ChartMill assigns a fundamental rating of 1 / 10 to MRT.


What is the valuation status for MRT stock?

ChartMill assigns a valuation rating of 1 / 10 to MARTI TECHNOLOGIES INC (MRT). This can be considered as Overvalued.


What is the profitability of MRT stock?

MARTI TECHNOLOGIES INC (MRT) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MRT stock?

The Earnings per Share (EPS) of MARTI TECHNOLOGIES INC (MRT) is expected to grow by 11.35% in the next year.